Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity ( Listeria monocytogenes (LM) is a facultative intracellular bacterium that is able to enter, survive, and multiply within both phagocytic and nonphagocytic cells (1-4). Immediately after entry, the LM bacteria are found in membrane-bound vacuoles (1). Phagosomal membranes are then disrupted by a secreted hemolysin, listeriolysin 0 (LLO), allowing release of bacteria into the cytoplasm (1, 3). Consequences of this event include escape from the bactericidal effects of phagolysosomal fusion, access to cytoplasmic nutrients, and interaction with the host cell cytoskeleton and the endogenous antigen-processing system.
Lysis of the endosomal membrane is followed by rapid growth in the cytoplasm. Cytoplasmic organisms become encapsulated by actin filaments in a process that requires a bacterial surface protein, ActA (1, 5) . Polar actin polymerization provides a propulsive force that allows the bacteria to move through the cytoplasm to the periphery of the cell. Pseudopod-like structures containing LM cells are then engulfed by neighboring cells (1) . Lysis of the newly formed double-membrane endosome allows LM to pass from cell to cell without leaving the cytoplasm. These observations provide an explanation for the importance of cell-mediated immunity in protection against listeriosis (6) .
The immune response to LM is multifactorial and involves the concerted action of neutrophils, macrophages, natural killer cells, CD4+ T cells, CD8+ T cells [cytotoxic T lymphocytes (CTLs)], and a plethora of cytokines (6) . Infection of The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
mice induces LM-specific, major histocompatibility complex (MHC) class I-restricted CD8+ T cells which are cytotoxic, secrete interferon y, and are able to confer protection following adoptive transfer (7, 8) . Proteins secreted by LM are the primary targets recognized by CD8+ T cells that arise during infection of mice (9, 10) . Foreign proteins expressed by recombinant LM can enter the MHC class I pathway and prime CD8+ T cells (11, 12) .
We tested the hypothesis that recombinant LM strains would serve as efficient vaccine vehicles for the induction of protective anti-viral immunity mediated by CD8+ CTLs. Lymphocytic choriomeningitis virus (LCMV) infection of mice was used as a model system to measure protective efficacy of vaccination. LCMV has been extensively used to study CD8+ T-cell-mediated anti-viral immunity (13) (14) (15) . Our results demonstrate that LM strains expressing the entire LCMV nucleoprotein (NP) or a specific H-2Ld-restricted CTL epitope are able to efficiently protect BALB/c mice against infection by immunosuppressive LCMV variants through a mechanism mediated by CD8+ T cells.
MATERIALS AND METHODS
Plasmid Construction. pHS-LV was constructed by cloning into pBR322 a 2.8-kb Taq I fragment from pE194ts (16) and a 5.6-kb HindIII-EcoRI LM chromosomal DNA fragment (17) with a unique Not I site introduced by oligonucleotide-directed mutagenesis. Antigen expression cassettes were constructed as follows. A 345-bp fragment of actA and a 290-bp fragment of hly containing their promoters and signal sequences (5, 18) were amplified by polymerase chain reaction. The entire NP coding region of LCMV Armstrong (19) , except the first ATG, was fused in frame to the third codon after the signal peptidase cleavage sites ofhly and actA. For the hly'-phoA fusion, a 1.1-kb Hae III fragment containing the hly promoter and encoding the N-terminal 288 aa of LLO (18) was translationally fused to the phoA gene which lacks its own promoter and signal sequence (20) . DNA encoding the NP epitope at aa 118-126 plus 3 flanking residues on each side (21) was inserted after the codon for LLO aa 133 within the hly'-phoA fusion. All constructs were sequenced through the fusion junctions and then cloned into the Not I site of pHS-LV.
Delivery of Fusion Constructs into the LM Genome.
pHS-LV derivatives were introduced into the wild-type LM strain 10403S by electroporation (22 (13) . Single-cell suspensions of splenocytes were used directly in standard 6-hr 51Cr-release assays using LCMVinfected BALB clone 7 (H-2d) cells as the target (13) .
RESULTS
A Genetic System for Site-Specific Integration of Antigen Expression Cassettes into the LM Genome. The genetic system shown in Fig. 1 allows stable, site-specific integration of antigen expression cassettes into the LM chromosome by sequential homologous recombination events. The system was designed to insert antigen cassettes between two convergent transcription units at a position downstream from a stem-loop structure which forms a predicted transcriptional terminator (17) . We expected that insertion of heterologous sequences at this position would not eliminate production of any known gene product or disrupt expression of nearby genes. Characterization of the recombinant strain HSL236 (Fig. 1 ) demonstrated that chromosomal integration of foreign DNA did not affect bacterial intracellular growth in J774 cells, intracellular actin polymerization as visualized by fluorescein-conjugated phallacidin staining, or plaque formation on L929 fibroblast monolayers (data not shown). In addition, all isolates tested that were recovered from infected animals or from prolonged in vitro culture retained the kanamycin-resistance marker encoded within antigen cassettes, indicating that recombinant strains are stable in vitro and in vivo.
The promoters and signal sequences of the hly and actA loci were chosen for expression and secretion of foreign antigens by LM. We anticipated that transcription, translation, and secretion under control of these regulatory elements would channel proteins to the endogenous pathway of antigen processing and presentation. The hly gene product, LLO, constitutes a major target for recognition by MHC class I-restricted CTLs which arise during infection (9) , and the ActA protein is made in large amounts in the cytoplasm of infected cells (24) . An hly'-phoA fusion was also constructed as a carrier for foreign epitopes (Fig. 1) . We reasoned that embedding a foreign epitope in LLO, a secreted protein with a native H-2d-restricted CD8+ T-cell epitope (9) , would facilitate secretion of the foreign epitope by LM and subsequent presentation by MHC class I molecules. The Escherichia coli phoA gene, encoding a secreted alkaline phosphatase, provides a functional assay for integrity and secretion of fusion proteins in E. coli, which correlates with secretion in LM (E.R.J., H.S., and J.F.M., unpublished data). Fusion to PhoA also allows export of fusion proteins by LM to be monitored with commercially available immunological reagents.
Recombinant LM Strains Expressing LCMV Antigens. In BALB/c (H-2d) mice a major portion of the LCMV-specific CTL response is directed against the viral NP, and a protective H-2Ld-restricted CD8+ T-cell epitope has been mapped to NP aa 118-126 (21, 25) . We constructed recombinant LM strains expressing the NP protein as well as the NP118-126 epitope (Fig. 1) . The entire NP coding region was fused to the promoters and signal sequences of actA (MSL223) or hly (EJL243), and sequences encoding the NP118-126 epitope were inserted within the hly'-phoA fusion (HSL236). Fusion constructs were integrated into the LM chromosome through double-crossover homologous recombination using the pHS-LV shuttle vector. Southern blot analysis confirmed integration of fusion constructs into the expected genomic site and resolution of plasmid sequences (data not shown). Localization and Regulated Expression of Antigens by Recombinant LM Strains. We expected that secretion of heterologous antigens by LM vaccine strains would promote efficient entry into the MHC class I antigen-processing pathway. Western blot analysis was used to detect fusion proteins in supernatants and total cell lysates of LM cultures grown under conditions in which the hly and actA promoters are maximally expressed (Fig. 2) . Polyclonal antibodies against the LCMV NP detected the full-length NP fusion product (62 kDa) in cell lysates and supernatants from MSL223 and EJL243 cultures. The presence of NP in both supernatant and total cell lysate fractions was probably due to inefficient secretion of NP, which is normally a cytoplasmic protein. In contrast, the 78-kDa LLO'-PhoA fusion protein containing the NP118-126 epitope was efficiently secreted by HSL236 into the culture supernatant and was barely detectable in HSL236 cell lysates. These results indicate that the ActA and LLO signal sequences are capable of directing fused polypeptides to the LM export pathway.
Expression of hly, actA, and most other known LM virulence factors is coordinately regulated by a positive regulatory factor, PrfA, in response to temperature (26) and pH (H.S. and J.F.M., unpublished data). We therefore determined whether in vitro expression of fusion proteins by recombinant vaccine strains also responded to these environmental signals. Immunoblots (Fig. 3) demonstrated that fusion proteins expressed by HSL236, MSL223, and EJL243 were produced at high levels when bacteria were grown at 37°C at neutral pH. Fusionprotein production was greatly reduced in cultures grown at 22°C or at acidic pH. This expression pattern was also observed for the native 58-kDa LLO protein (Fig. 3) and was identical to that of prfA-regulated promoters examined by primer extension (data not shown). Thus, antigen expression in our recombinant strains is regulated in a manner identical to the chromosomal hly and actA loci. The fusion proteins are therefore predicted to be expressed during intracellular growth. (13, 14) . The ability to control infection by these immunosuppressive variants serves as a definitive marker for in vivo CTL memory (15) .
BALB/c mice were immunized and boosted i.v. with sublethal doses of LM vaccine strains or with the wild-type strain 10403S. Four weeks after boosting, immunized mice were challenged with LCMV clone 28b. At day 3 after challenge, all mice had equivalent virus titers of 103 pfu/ml of serum (data not shown). At day 8, mice immunized with the 10403S control strain had high virus titers, averaging 4 x 105 pfu/ml of serum. These mice showed obvious signs of illness, including marked lethargy, matted fur, and closed eyes, all of which are characteristic of systemic infection by immunosuppressive LCMV variants. In contrast, all mice vaccinated with MSL223, EJL243, or HSL236 remained healthy and efficiently controlled viral replication (Fig. 4A) . Spleens from 10403S control mice were severely atrophied as a result of immunosuppression by LCMV clone 28b and their splenocytes were unable to specifically lyse LCMV-infected target cells. In contrast, all spleens obtained from mice vaccinated with recombinant LM strains were enlarged, and splenocytes were highly cytotoxic to virally infected targets when measured in direct ex vivo CTL assays (Fig. 4B) . Results suggest that immunization with LM vaccine strains generates protective CD8+ CTLs. To investigate the role of CD8+ T cells in LCMV clearance by LM-immunized mice, we specifically depleted this effector cell population and determined the effect on protection against LCMV. Mice immunized with MSL223 were injected intraperitoneally with a rat monoclonal antibody against the mouse CD8 molecule at day -2, 0, +2, and +4 of LCMV challenge. In vivo administration of anti-CD8 antibody resulted in depletion of >95% of circulating CD8 T cells as shown by flow cytometry. Mice immunized with 10403S and mice vaccinated with MSL223 without CD8 depletion were included as controls. Mice immunized with MSL223 eliminated viral infection by day 15 (Fig. 5) . Treatment of MSL223-immunized mice with anti-CD8 antibody resulted in viral titers that were indistinguishable from those of 10403S control mice (>105 pfu/ml). These results demonstrate that protective anti-viral immunity generated by a recombinant LM vaccine strain is mediated by CD8+ T cells.
DISCUSSION
Attempts to use live bacteria as delivery vehicles for stimulating CD8+ CTLs have focused on Salmonella (27, 28) , bacillus Calmette-Guerin (29, 30) , and most recently LM (11, 12) . A major difference between these organisms is that LM is uniquely endowed with the ability to enter the cytoplasm of infected cells, allowing proteins secreted by the bacteria to directly access the MHC class I antigen-processing pathway leading to antigen presentation to CD8+ T cells. Induction of CTL responses against viral antigens has been described with recombinant bacillus Calmette-Guerin (28, 29) and LM (12), but protection against heterologous pathogens has not been reported. In the present study we demonstrate that immunization with recombinant LM strains can protect mice against viral infection.
Our genetic system allows the construction of recombinant LM strains in which antigen cassettes are integrated into a specific site in the bacterial genome. Chromosomal integration has an advantage over plasmid-based systems in that it does not require the presence of antibiotics to select for retention. Antigen cassettes were inserted between two convergent transcription units in a well-defined region of the LM chromosome, and integration at this location did not affect intracellular growth or cell-to-cell spread. Both the actA and hly promoters were able to direct expression of LCMV antigens and their expression was regulated in vitro in a manner identical to the chromosomal act;A and hly loci. Both the ActA and LLO signal sequences were effective in promoting secretion of LCMV NP, although a significant amount of cell-associated antigen was detected in either case. In contrast, the NP118-126 epitope buried within an LLO'-PhoA fusion protein was efficiently translocated across the bacterial cytoplasmic membrane. We anticipate that our antigen expression and secretion system will be broadly applicable to a variety of antigens of interest, although the extent of membrane translocation will depend on the particular protein being expressed. The relationship among regulated expression, secretion, and antigen processing remains to be determined. The interaction between LCMV and its natural host, the mouse, has been extensively used for the analysis of antiviral CD8+ CTL responses (13) (14) (15) . We have therefore chosen LCMV as a model pathogen to investigate the utility of LM-based vaccines which are designed to induce protective cell-mediated immunity. Recombinant LM strains expressing the entire LCMV NP or a specific H-2Ld-restricted CTL epitope (NP aa 118-126) were protective against subsequent challenge with immunosuppressive variants of LCMV, and protection was correlated with induction of LCMV-specific CTLs. Protection generated by a LM strain expressing a single MHC class I-restricted epitope strongly suggested that immunity was mediated by CD8+ T cells. This was confirmed by in vivo depletion of CD8+ T cells, which eliminated protection against viral infection. The LM-LCMV model will therefore be useful for addressing a variety of questions relating to MHC class I antigen processing and presentation as well as vaccine design.
The magnitude and duration of immunological memory resulting from vaccination are likely to depend on a variety of factors, including adjuvant effects of the particular vaccine delivery vehicle. An attractive feature of recombinant vaccines based on LM is the multifaceted interaction between this organism and the host immune system. In addition to CD8+ T cells, LM infection induces antigen-specific CD4+ T helper cells that are MHC class II-restricted and are primarily of the Th, subclass (31) . In vitro studies have linked the ability of LM to induce a Thl-type response with its ability to stimulate production of interleukin 12 by macrophages (32) . LM may therefore function simultaneously as a vehicle for delivering foreign antigens to the MHC class I pathway and as an adjuvant promoting development of cell-mediated immunity.
